Hematologic Malignancy

Most recent genetic diagnosis by using PCR and next-generation sequencing (NGS) has significantly improved the understanding of molecular mechanism of hematological malignancies, leading to the right choice of molecular targeting drugs for precision therapy for the individual patients in clinic. To help precise medicine in hematological malignancies such as leukemia, lymphoma, and multiple myeloma, MEDx has developed a variety of blood cancer tests containing panel gene assays and single target tests applied to the diagnosis and treatment of hematological proliferative disorders, and to the monitoring of recurrence and drug resistance of hematological malignancies.

• Category	• Tests	• Test Targets	• Test Methods	• Test Code
Diagnostic / Prognostic Markers	JAK2-V617F Gene Mutation Detection	JAK2-V617F Mutation	QPCR	1000034
Diagnostic / Predictive / Prognostic Markers	BCR-ABL Fusion Detection	BCR-ABL Fusion	QPCR	1000046
Diagnostic Markers	SBCMA Testing	SBCMA	ELISA	1000047
Panel Gene Detection	HemeCDx Panel Testing （Mutation Version）	505 Genes	NGS	1000044
	HemeCDx Panel Testing （Full Version）	505 Genes, Containing 99 Fusions	NGS	1000045
	HemeCDx Panel Testing （Fusion Version）	99 Fusion Genes	NGS	1000052
	Lymphoma HEMECDx Panel Testing	188 Genes	NGS	1000060
	Leukemia HEMECDx Panel Testing	158 Genes	NGS	1000061
	RNAseq Fusion And Mutation Testing	Whole Transcriptome	NGS	1000072

If you have any of the following needs, feel free to contact us or email us at inquiry@MEDxTMC.net . We will reply within 24 hours.

1. Customized or bulk orders of IVD/CDx products.

2. Get a quote for IVD/CDx products

3. Become our distributor

4. Get customized pharmaceutical service solutions

5.Learn more about our technology and R&D